Browse by Medical Category
Research at Mass General
The MGH Gordon PET Core is cGMP/FDA registered PET drug manufacturer. It provides investigators with required personnel, equipment and services to design and conduct research studies using positron emission tomography.
For questions related to human and large animal imaging, please contact:Steven WeiseSr. Research Technologist, PET ImagingEmail: email@example.com Phone: 617-726-5299
For questions related to small animal imaging, please contact:Julia Scotton, B.S., CNMT, RT(N)(CT)Senior Research Technologist and Safety ManagerEmail: firstname.lastname@example.org Phone: 617-643-1967
For questions related to drug production, please contact:
Daniel Yokell, Pharm.D.Manager, PET Production ChemistryPhone: (617) 643-7541Fax: (617) 726-5123Email: email@example.com
For questions related to study budgets, invoices and payments, please contact:Ramzi El FakhriBusiness ManagerPhone: 617-724-7212Email: firstname.lastname@example.org
For other inquiries, please contact:Georges El Fakhri, Ph.D.Director, MGH Gordon PET CorePhone: (617) 726-9640Fax: (617) 726-6165Email: email@example.com
Main services include:
The Core has synthesized over 20 compounds for clinical evaluation and routine use for neurology, cardiology and oncology. In addition, it has pioneered the use of 18F Tau imaging agents for neurodegenerative diseases such as Alzheimer’s disease and traumatic brain injuries.
*FDA approved, MGH PET Center holds FDA marketing authorization
**FDA approved, available through local commercial nuclear pharmacies
†Active IND held by MGH Gordon PET Core
‡Available under Radioactive Drug Research Committee (RDRC) oversight
The MGH Gordon PET Core can validate a radiopharmaceutical for clinical research use.
Please send inquiries to:
Daniel YokellAssociate Director, Radiopharmacy and Regulatory Affairs, MGHEmail: firstname.lastname@example.org or Phone: 617-643-7541.
Please contact PET core for rate
The Core commits its best efforts to successfully complete scheduled studies. However, given the very nature of many PET studies that rely on manufacturing of the radiopharmaceutical and in vivo imaging, the Core cannot cover costs associated with uncompleted studies due to equipment failure or circumstances outside of our control.
A fee, up to the cost of the cancelled service, can be charged in relation with a study in the event of a last minute cancellation or a no-show.
* A Partners investigator using a Partners fund is considered an internal user and will be subject to the institutional overhead rate applied by Partners Research Management. The external user fee comprises a direct fee negotiated with the PET Core plus an overhead component. The overhead rate set by Partners is 44% for external academic users and 59% for external industry users.
Back to Top